Amazing how these Bio's jump on Phase I news for NASH and the SP in general in the $7 bucks range with only one drug in Pipeline and no revenue.

But they are on NASDAQ, cant wait till we uplist!

https://seekingalpha.com/news/3535512-hepion-...-nash-data